ISAL 2019 | Frontline FLAG-Ida for high-risk AML: data from the UK NCRI AML17 trial

Alan Burnett

“The UK NCRI AML17 trial (ISRCTN55675535) investigated a number of interventions for younger patients with acute myeloid leukemia (AML). We spoke to Alan Burnett, MD, FRCP, of Cardiff University, Cardiff, UK, about the results of the comparison of FLAG-Ida and daunorubicin with clofarabine for high-risk AML in the trial, which were recently published. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.”

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter